Notably, combining ruxolitinib with standard treatment drugs has shown significant therapeutic effects in CRLF2-rearranged Ph-like ALL acute lymphoblastic leukemia [94]. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.